We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+23.73%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$8.79B
AUM Growth
-$8.56B
Cap. Flow
-$9.86B
Cap. Flow %
-112.21%
Top 10 Hldgs %
80.97%
Holding
105
New
4
Increased
25
Reduced
11
Closed
21

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$152M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$74.3M
3
RVMD icon
Revolution Medicines
RVMD
+$59M
4
REPL icon
Replimune Group
REPL
+$57.6M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$46M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$9.45B
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$337M
3
ONC
BeOne Medicines Ltd
ONC
+$199M
4
SWTX
SpringWorks Therapeutics
SWTX
+$69.4M
5
ROIV icon
Roivant Sciences
ROIV
+$41.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.37%
2 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.4B
$2.27B 25.85%
36,179,122
+556
+0% +$31.4K
ONC
2
BeOne Medicines Ltd
ONC
$34B
$1.91B 21.69%
10,568,897
-1,100,000
-9% -$199M
ACAD icon
3
Acadia Pharmaceuticals
ACAD
$4.51B
$1.34B 15.27%
42,864,612
– –
MDGL icon
4
Madrigal Pharmaceuticals
MDGL
$12.6B
$456M 5.19%
1,969,798
+424,685
+27% +$74.3M
RYTM icon
5
Rhythm Pharmaceuticals
RYTM
$7.31B
$294M 3.35%
6,398,365
-303,984
-5% -$9.59M
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$242M 2.76%
4,121,440
+2,711,656
+192% +$152M
IMCR icon
7
Immunocore
IMCR
$1.7B
$172M 1.96%
2,520,731
– –
KYMR icon
8
Kymera Therapeutics
KYMR
$8.66B
$153M 1.74%
5,995,928
+1,245,528
+26% +$22.3M
RVMD icon
9
Revolution Medicines
RVMD
$38.4B
$148M 1.68%
5,148,657
+2,457,164
+91% +$59M
ABCL icon
10
AbCellera Biologics
ABCL
$1.65B
$131M 1.49%
22,909,753
+2,146,430
+10% +$9.95M
ROIV icon
11
Roivant Sciences
ROIV
$23.6B
$85.3M 0.97%
7,593,024
-4,284,147
-36% -$41.8M
REPL icon
12
Replimune Group
REPL
$455M
$80.5M 0.92%
9,545,336
+4,967,056
+108% +$57.6M
TRDA icon
13
Entrada Therapeutics
TRDA
$254M
$73.4M 0.84%
4,865,819
– –
RARE icon
14
Ultragenyx Pharmaceutical
RARE
$2.46B
$70.1M 0.8%
1,466,547
+100,000
+7% +$3.88M
CERE
15
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$67.8M 0.77%
+1,600,000
New +$46M
IMTX icon
16
Immatics
IMTX
$1.23B
$61.5M 0.7%
5,838,853
+198,037
+4% +$1.82M
BCRX icon
17
BioCryst Pharmaceuticals
BCRX
$2.42B
$60.7M 0.69%
10,126,176
-2,584,642
-20% -$15M
ARGX icon
18
argenx
ARGX
$55.2B
$57.5M 0.65%
151,215
– –
DNLI icon
19
Denali Therapeutics
DNLI
$3.78B
$56M 0.64%
2,607,196
+315,193
+14% +$6.24M
AKRO
20
DELISTED
Akero Therapeutics
AKRO
$55.3M 0.63%
2,368,378
– –
KOD icon
21
Kodiak Sciences
KOD
$2.51B
$52.6M 0.6%
17,310,490
– –
KNSA icon
22
Kiniksa Pharmaceuticals
KNSA
$6.23B
$49.3M 0.56%
2,809,577
– –
XENE icon
23
Xenon Pharmaceuticals
XENE
$6.1B
$45.8M 0.52%
993,679
+242,040
+32% +$8.55M
PRLD icon
24
Prelude Therapeutics
PRLD
$376M
$43.2M 0.49%
10,123,824
– –
CERS icon
25
Cerus
CERS
$575M
$42.1M 0.48%
19,477,339
+2,237,838
+13% +$3.69M
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, Baker Bros. Advisors held 105 positions worth $8.79B, down 49% from $17.4B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Baker Bros. Advisors withdrew a net $9.86B in Q4 2023, closing 21 positions and reducing 11 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $9.45B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

Against the trend, Baker Bros. Advisors opened a new position in Cerevel Therapeutics Holdings, Inc. Common Stock worth $67.8M.

  • Baker Bros. Advisors's largest Q4 2023 buy was Cerevel Therapeutics Holdings, Inc. Common Stock: 1,600,000 shares worth $67.8M.
  • Baker Bros. Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q4 2023, an estimated $152M increase.
  • Baker Bros. Advisors's biggest Q4 2023 reduction was BeOne Medicines Ltd, cutting an estimated $199M.
  • Baker Bros. Advisors fully exited Seagen Inc. Common Stock in Q4 2023, selling an estimated $9.45B.
  • Baker Bros. Advisors's ten largest holdings make up 81% of its $8.79B portfolio in Q4 2023.
  • Baker Bros. Advisors opened 4 new positions and closed 21 in Q4 2023.
  • Baker Bros. Advisors's portfolio value fell 49% quarter-over-quarter to $8.79B.

Based on Baker Bros. Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.